

Multiple Criteria Decision Analysis (MCDA) for evaluating Technology Assessment and beyond: The Advance Value

Social Science and Medicine

188, 137-156

DOI: [10.1016/j.socscimed.2017.06.024](https://doi.org/10.1016/j.socscimed.2017.06.024)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Medical Informatics and Decision Making, 2017, 17, 149.	1.5	23
2	Does MCDA Trump CEA?. Applied Health Economics and Health Policy, 2018, 16, 147-151.	1.0	17
3	DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK. International Journal of Technology Assessment in Health Care, 2018, 34, 163-171.	0.2	8
4	From Health Technology Assessment to Health Technology Sustainability. Sustainability, 2018, 10, 4748.	1.6	9
5	Valuing health states: is the MACBETH approach useful for valuing EQ-5D-3L health states?. Health and Quality of Life Outcomes, 2018, 16, 235.	1.0	4
6	A decision support tool for supporting individuals living with long-term conditions make informed choices: LTC-Choices tool for continuous healthcare. Journal of Decision Systems, 2018, 27, 123-131.	2.2	2
7	Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development?. Frontiers in Public Health, 2018, 6, 287.	1.3	38
8	Value-Based Pricing in Latin America: How Far Away Are We?. Value in Health Regional Issues, 2018, 17, 219-223.	0.5	5
9	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health, 2018, 6, 328.	1.3	102
10	Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden. MDM Policy and Practice, 2018, 3, 238146831879621.	0.5	5
11	MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING. International Journal of Technology Assessment in Health Care, 2018, 34, 519-526.	0.2	14
12	Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?. Patient, 2018, 11, 249-252.	1.1	44
13	A multi-criteria sustainability assessment framework: development and application in comparing two food waste management options using a UK region as a case study. Environmental Science and Pollution Research, 2018, 25, 35821-35834.	2.7	36
14	Hospital staff perspectives towards health technology assessment: data from a multidisciplinary survey. Health Research Policy and Systems, 2019, 17, 72.	1.1	9
15	Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. Global & Regional Health Technology Assessment, 2019, 2019, 228424031988053.	0.2	5
16	Setting Strategic Objectives for the Coalition for Epidemic Preparedness Innovations: An Exploratory Decision Analysis Process. Interfaces, 2019, 49, 430-446.	1.6	4
17	Doenças raras, drogas órfãs e as políticas para avaliação e incorporação de tecnologias nos sistemas de saúde. Sociologias, 2019, 21, 332-364.	0.1	7
18	Could or Should We Use MCDA in the French HTA Process?. Pharmacoeconomics, 2019, 37, 1417-1419.	1.7	5

#	ARTICLE	IF	CITATIONS
19	Multicriteria Decision Analysis of Drinking Water Source Selection in Southwestern Bangladesh. <i>Journal of Water Resources Planning and Management - ASCE</i> , 2019, 145, .	1.3	17
20	Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. <i>European Journal of Health Economics</i> , 2019, 20, 891-918.	1.4	45
21	Quantifying Preferences in Drug Benefitâ€Risk Decisions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 955-959.	2.3	19
22	Healthcare decisionâ€making applications using multicriteria decision analysis: A scoping review. <i>Journal of Multi-Criteria Decision Analysis</i> , 2019, 26, 62-83.	1.0	46
23	Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment. <i>PLoS ONE</i> , 2019, 14, e0225938.	1.1	18
24	Comment on: â€œDoes MCDA Trump CEA?â€ <i>Applied Health Economics and Health Policy</i> , 2019, 17, 123-124.	1.0	3
25	Why We Donâ€™t Need â€Unmet Needsâ€! On the Concepts of Unmet Need and Severity in Health-Care Priority Setting. <i>Health Care Analysis</i> , 2019, 27, 26-44.	1.4	15
26	Combining Quantitative Risk Assessment of Human Health, Food Waste, and Energy Consumption: The Next Step in the Development of the Food Cold Chain?. <i>Risk Analysis</i> , 2019, 39, 906-925.	1.5	34
28	Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. <i>Social Science and Medicine</i> , 2020, 246, 112595.	1.8	23
29	A methodology based on multiple criteria decision analysis for combining antibiotics in empirical therapy. <i>Artificial Intelligence in Medicine</i> , 2020, 102, 101751.	3.8	4
30	Why TOPSIS does not always give correct results?. <i>Procedia Computer Science</i> , 2020, 176, 3591-3600.	1.2	14
31	Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies. <i>Pharmacoeconomics</i> , 2020, 38, 1297-1308.	1.7	23
32	Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 434-439.	0.2	6
33	ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations. <i>Value in Health</i> , 2020, 23, 1040-1048.	0.1	13
34	Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countriesâ€”A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses. <i>Frontiers in Pharmacology</i> , 2020, 11, 1203.	1.6	7
35	Organizational aspect in healthcare decision-making: a literature review. <i>Journal of Market Access & Health Policy</i> , 2020, 8, 1810905.	0.8	10
36	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020, 40, 830-845.	1.2	8
37	Energy Efficiency contribution to sustainable development: A multi-criteria approach in Greece. <i>Energy Sources, Part B: Economics, Planning and Policy</i> , 2020, 15, 572-604.	1.8	15

#	ARTICLE	IF	CITATIONS
38	Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 269-279.	1.8	29
39	A New Decision Model Approach for Health Technology Assessment and a Case Study for Dialysis Alternatives in Turkey. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3608.	1.2	15
40	Global Pharmaceutical Policy. , 2020, , .		7
41	Assessment and prioritization of the WHO "best buys" and other recommended interventions for the prevention and control of non-communicable diseases in Iran. <i>BMC Public Health</i> , 2020, 20, 333.	1.2	50
42	Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice. <i>JCO Oncology Practice</i> , 2020, 16, e298-e305.	1.4	6
43	"It takes two to tango": Bridging the gap between country need and vaccine product innovation. <i>PLoS ONE</i> , 2020, 15, e0233950.	1.1	7
44	Automated hospital pharmacy supply chain and the evaluation of organisational impacts and costs. <i>Supply Chain Forum</i> , 2020, 21, 206-218.	2.7	11
45	Framework for Drug Formulary Decision Using Multiple-Criteria Decision Analysis. <i>Medical Decision Making</i> , 2020, 40, 438-447.	1.2	3
46	"Without data, you're just another person with an opinion". <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 147-154.	0.7	11
47	Strategizing sustainability in the banking industry using fuzzy cognitive maps and system dynamics. <i>International Journal of Sustainable Development and World Ecology</i> , 2021, 28, 93-108.	3.2	18
48	Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e31.	0.2	6
49	Technology assessment framework for precision health applications. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e67.	0.2	5
50	Bright line or lottery? On significance and value in medical decision making. <i>Journal of Market Access & Health Policy</i> , 2021, 9, 1981574.	0.8	1
51	Practices of decision making in priority setting and resource allocation: a scoping review and narrative synthesis of existing frameworks. <i>Health Economics Review</i> , 2021, 11, 2.	0.8	12
52	Multiple criteria decision analysis for medicine reimbursement in the Lebanese context. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, .	0.2	0
53	An MCDM-Based Health Technology Assessment (HTA) Study for Evaluating Kidney Stone Treatment Alternatives. <i>Contributions To Management Science</i> , 2021, , 99-130.	0.4	0
54	The Need for Novel Approaches in Assessing the Value of COVID-19 Vaccines. <i>American Journal of Public Health</i> , 2021, 111, 205-208.	1.5	2
55	Using Decision Science for Monitoring Threatened Western Snowy Plovers to Inform Recovery. <i>Animals</i> , 2021, 11, 569.	1.0	3

#	ARTICLE	IF	CITATIONS
56	Incorporating patients'™ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 183-195.	0.7	2
57	Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 13.	0.6	8
58	Mathematically formulated key performance indicators for design and evaluation of treatment trains for resource recovery from urban wastewater. <i>Journal of Environmental Management</i> , 2021, 282, 111916.	3.8	15
59	Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy. <i>Frontiers in Medical Technology</i> , 2021, 3, 629750.	1.3	4
60	Value-based decision-making for orphan drugs with multiple criteria decision analysis: burosumab for the treatment of X-linked hypophosphatemia. <i>Current Medical Research and Opinion</i> , 2021, 37, 1021-1030.	0.9	2
61	Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review. <i>PharmacoEconomics - Open</i> , 2021, 5, 605-612.	0.9	8
62	A systematic review of moral reasons on orphan drug reimbursement. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 292.	1.2	17
63	Patient and Payer Preferences for Additional Value Criteria. <i>Frontiers in Pharmacology</i> , 2021, 12, 690021.	1.6	7
64	Proposal for capturing patient experience through extended value frameworks of health technologies. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 936-947.	0.5	4
65	Multicriteria decisions and portfolio analysis: land acquisition for biological and social objectives. <i>Ecological Applications</i> , 2021, 31, e02420.	1.8	5
66	What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks. <i>Value in Health</i> , 2022, 25, 302-317.	0.1	11
67	The association between healthcare resource allocation and health status: an empirical insight with visual analytics. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2023, 31, 1035-1057.	0.8	2
68	Value Assessment Frameworks in Latin America: "œll buono, il brutto e il cattivo". <i>Value in Health Regional Issues</i> , 2021, 26, 50-55.	0.5	0
69	Towards proper consumer choices - MCDM based product selection. <i>Procedia Computer Science</i> , 2021, 192, 1347-1358.	1.2	8
70	A Six Sigma DMAIC methodology as a support tool for Health Technology Assessment of two antibiotics. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 3469-3490.	1.0	22
71	Medicines Pricing: Limitations of Existing Policies and New Models. , 2020, , 99-137.		2
72	Review of the Literature on Multicriteria Methods Applied in the Field of Public Security. <i>Universal Journal of Management</i> , 2017, 5, 549-562.	0.2	9
73	Moving Towards Accountability for Reasonableness "œ A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study. <i>International Journal of Health Policy and Management</i> , 2019, 8, 424-443.	0.5	10

#	ARTICLE	IF	CITATIONS
75	Patients' Preferences Regarding Osteoarthritis Medications: An Adaptive Choice-Based Conjoint Analysis Study. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 2501-2515.	0.8	5
76	Artificial Intelligence and Health Technology Assessment: Anticipating a New Level of Complexity. <i>Journal of Medical Internet Research</i> , 2020, 22, e17707.	2.1	53
77	A heuristic for the selection of appropriate diagnostic tools in large-scale sugarcane supply systems. <i>AIMS Agriculture and Food</i> , 2018, 4, 1-26.	0.8	5
79	A WHO tool for risk-based decision making on blood safety interventions. <i>Transfusion</i> , 2021, 61, 503-515.	0.8	3
80	Methods for the health technology assessment of complex interventions: a protocol for a scoping review. <i>BMJ Open</i> , 2020, 10, e039263.	0.8	0
81	Ordered weighted average based grouping of nanomaterials with Arsinh and dose response similarity models. <i>NanoImpact</i> , 2022, 25, 100370.	2.4	2
82	Methods for the health technology assessment of complex interventions: a protocol for a scoping review. <i>BMJ Open</i> , 2020, 10, e039263.	0.8	0
83	A Scoping Review of Different Methods of Assessing the Impact of New Medical Technologies at Early Stages of Development. <i>Medical Journal of the Islamic Republic of Iran</i> , 2021, 35, 141.	0.9	0
84	The Online Elicitation of Personal Utility Functions (OPUF) tool: a new method for valuing health states. <i>Wellcome Open Research</i> , 0, 7, 14.	0.9	7
85	How innovation can be defined, evaluated and rewarded in health technology assessment. <i>Health Economics Review</i> , 2022, 12, 1.	0.8	16
86	Understanding innovation of health technology assessment methods: the IHTAM framework. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e16.	0.2	2
87	Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting. <i>Clinical Drug Investigation</i> , 2022, 42, 75-85.	1.1	2
88	Multicriteria decision analysis in health care decision in oncology: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 365-380.	0.7	3
90	Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework. <i>PLoS ONE</i> , 2022, 17, e0268584.	1.1	5
91	Application of a Mixed Methods Multi-Criteria Decision Analysis Framework in Integrated Health Care. <i>International Journal of Integrated Care</i> , 2022, 22, .	0.1	1
92	Crit�rios de decis�o para a aloca�o de recursos: uma an�lise de relat�rios da CONITEC na �rea de oncologia. <i>Ciencia E Saude Coletiva</i> , 2022, 27, 2563-2572.	0.1	0
93	Decision criteria for resource allocation: an analysis of CONITEC oncology reports. <i>Ciencia E Saude Coletiva</i> , 2022, 27, 2563-2572.	0.1	1
95	Knowledge Mapping of Multicriteria Decision Analysis in Healthcare: A Bibliometric Analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	10

#	ARTICLE	IF	CITATIONS
96	A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, .	0.2	2
97	How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada. <i>Health Policy</i> , 2022, 126, 1130-1143.	1.4	4
98	External validity of multi-criteria preference data obtained from non-random sampling: measuring cohesiveness within and between groups. <i>Annals of Operations Research</i> , 0, , .	2.6	0
99	Endpoints for safety in health technology assessmentsâ€“The experiences of the Danish Medicines Council. <i>Health Policy and Technology</i> , 2022, 11, 100692.	1.3	0
100	Measurement and valuation of the attributes of innovation of healthcare technologies: a systematic review. <i>Journal of Medical Economics</i> , 2022, 25, 1176-1184.	1.0	0
101	Characterizing attributes of innovation of technologies for healthcare: a systematic review. <i>Journal of Medical Economics</i> , 2022, 25, 1158-1166.	1.0	2
103	Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil. <i>SaÃºde Em Debate</i> , 2022, 46, 886-905.	0.1	0
104	The Use of Multicriteria Decision Analysis to Support Decision Making in Healthcare: An Updated Systematic Literature Review. <i>Value in Health</i> , 2023, 26, 780-790.	0.1	6
105	Value Insider Season 1 Episode 6: How Will Market Access and Value Demonstration Evolve? (Future) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.8	0
106	The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals. <i>Applied Health Economics and Health Policy</i> , 0, , .	1.0	0
108	Life cycle engineering of space systems: Preliminary findings. <i>Advances in Space Research</i> , 2023, 72, 2917-2935.	1.2	3
109	Desirabilityâ€“doability group judgment framework for the collaborative multicriteria evaluation of public policies. <i>International Transactions in Operational Research</i> , 2023, 30, 3654-3686.	1.8	1
110	Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force. <i>Value in Health</i> , 2023, 26, 449-460.	0.1	6
111	Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study. <i>Pharmacoeconomics</i> , 2023, 41, 439-455.	1.7	2
112	Application of weighted aggregated sum product assessment and geographical information system for urban development zoning. <i>Asia-Pacific Journal of Regional Science</i> , 0, , .	1.1	0
113	Patient-based evidence: its role in decision making on end-of-life, orphan, and ultra-orphan medicines. <i>International Journal of Technology Assessment in Health Care</i> , 2023, 39, .	0.2	0
114	The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework. <i>Applied Health Economics and Health Policy</i> , 2023, 21, 373-384.	1.0	2
115	Sustainable Energy Strategies for Power Purchase Agreements (PPAs). <i>Sustainability</i> , 2023, 15, 6638.	1.6	0

#	ARTICLE	IF	CITATIONS
134	A Critical Review of Multi Criteria Decision Analysis Method for Decision Making and Prediction in Big Data Healthcare Applications. Communications in Computer and Information Science, 2024, , 89-100.	0.4	0